CEBPA and acute myeloid leukemia: We demonstrate that increased GATA2 levels are disadvantageous to CEBPADM leukemic cells and that this can be counteracted by TET2 loss thus providing an explanation for the co-occurrence of CEBPA and TET2 lesions in AML.